Effects of valsartan vs amlodipine and achieved lower blood pressure on the incidence of end-stage kidney disease: The VALUE Trial
In hypertensive patients with a high cardiovascular risk, valsartan and amlodipine have a similar impact on the incidence of end-stage kidney disease. Achieving SBP <135 mmHg, averaging 128.8/77.3 mmHg, is highly efficacious in kidney protection.
Authors
- Julian E. Mariampillai (ORCID: https://orcid.org/0000-0002-3857-9797)
- Camilla Lund Søraas (ORCID: https://orcid.org/0000-0002-3964-4351)
- Knut Liestøl (ORCID: https://orcid.org/0000-0002-7929-582X)
- Anne Cecilie K. Larstorp (ORCID: https://orcid.org/0000-0002-0223-9248)
- M. A. Weber (ORCID: https://orcid.org/0009-0006-8360-3545)
- Lene V. Halvorsen (ORCID: https://orcid.org/0000-0003-0411-2459)
- Michel Burnier (ORCID: https://orcid.org/0000-0003-1283-8487)
- Sondre Heimark (ORCID: https://orcid.org/0000-0001-8050-7765)
- Kenneth Jamerson (ORCID: https://orcid.org/0000-0003-2936-0619)
- Morten Rostrup (ORCID: https://orcid.org/0000-0002-6388-4072)
- Eirik Olsen (ORCID: https://orcid.org/0009-0008-6187-658X)
- Giuseppe Mancia (ORCID: https://orcid.org/0000-0003-0942-3176)
- Sverre E. Kjeldsen (ORCID: https://orcid.org/0000-0003-2389-0272)
- Maria H. Mehlum (ORCID: https://orcid.org/0000-0002-8885-2798)
- Roland E. Schmieder
- Stevo Julius
- Aud Høieggen
Institutions
- Oslo University Hospital (NO)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- SUNY Downstate Health Sciences University (US)
- University of Oslo (NO)
- Norwegian University of Science and Technology (NO)
- University of Michigan (US)
- Akershus University Hospital (NO)
- St Olav's University Hospital (NO)
- University of Milano-Bicocca (IT)
- University of Lausanne (CH)
Publication Details
- Journal
- European Journal of Internal Medicine
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1016/j.ejim.2024.12.021
- Citations
- 7
- Primary Topic
- Blood Pressure and Hypertension Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.81
Funders
- Novartis Pharmaceuticals Corporation
- Norges Forskningsråd
- Novartis Pharma